Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ZBF
|
|||
| Former ID |
DIB015098
|
|||
| Drug Name |
E-1224
|
|||
| Synonyms |
BMS-292655; BMS-315801; BMS-379224; Ravuconazole prodrugs, BMS; Ravuconazole back-up compounds, Eisai; Ravuconazole prodrug (fungal infection), Brain Factory; Ravuconazole prodrugs, Bristol-Myers Squibb
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fungal infection [ICD-11: 1F29-1F2F; ICD-10: B35-B49; ICD-9: 110-118] | Phase 2 | [1] | |
| Company |
Bristol-Myers Squibb Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H20BNO3
|
|||
| Canonical SMILES |
B1(OC(C(O1)(C)C)(C)C)C=CC2=C(N=CC=C2)C(=O)C
|
|||
| InChI |
1S/C15H20BNO3/c1-11(18)13-12(7-6-10-17-13)8-9-16-19-14(2,3)15(4,5)20-16/h6-10H,1-5H3/b9-8+
|
|||
| InChIKey |
DAQLKAUMCVWOCH-CMDGGOBGSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Candida Cytochrome P450 51 (Candi ERG11) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01489228) Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease. U.S. National Institutes of Health. | |||
| REF 2 | Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist. 2012 Dec;2:236-242. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.